Bio Refine
Endovascular Annuloplasty Remodeling System
StartupBio Refine is a Tel Aviv-Yafo-based startup in the Health Tech & Life Sciences sector, established in 2019. Endovascular Annuloplasty Remodeling System. The company has raised a total of $1.4M across 2 funding rounds, currently at the Seed stage. Bio Refine was founded by Boaz Shenhav. Key investors include Peregrine Ventures. The company has 1-10 employees.
With $1.4M in total funding, Bio Refine is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StageSeed
- ProductR&D
- ModelB2B
- Employees1-10
- HQTel Aviv-Yafo
- Last Round$500K
- Peregrine Ventures
Boaz ShenhavCo-Founder & CEO
What does Bio Refine do?
Bio Refine has developed an endovascular annuloplasty remodeling system, without an implant, for the repair of mitral and tricuspid heart valves. The technology will offer treatment to patients who cannot currently be treated due to the high risk of open surgery. The implantless solution offers multiple advantages. With significantly easier regulation, it uses a standard endovascular approach, and the procedure is safe, implant free, repeatable, and does not prevent ancillary procedures.
How much funding has Bio Refine raised?
Bio Refine has raised $1.4M in total funding across 2 rounds. The company is currently at the Seed stage. Key investors include Peregrine Ventures.
Who founded Bio Refine?
Bio Refine was founded in 2019 by Boaz Shenhav (Co-Founder & CEO).
What sector is Bio Refine in?
Bio Refine operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics. Target customers: Healthcare & Life Sciences, Healthcare, Providers.
Where is Bio Refine located?
Bio Refine is based in Anatot St 36, Tel Aviv-Yafo, Israel.